BFM
IPXL

Boothbay Fund Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Boothbay Fund Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-19,184
Closed -$614K – 766
2016
Q1 		$614K Buy
+19,184
New +$674K 0.16% 167

Other funds holding IPXL

HP
Hound Partners New York $863M AUM 11.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Boothbay Fund Management's IPXL Position: Q2 2016 in Review

Boothbay Fund Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2016, closing a stake of 19,184 shares — an estimated $614K sold.

Boothbay Fund Management first reported a position in IPXL in Q1 2016 and held it in 1 quarter. The position peaked at $614K in Q1 2016. 198 funds tracked by Wall St. Rank hold IPXL as of Q2 2016.

  • Boothbay Fund Management reported no remaining Impax Laboratories, Inc. position as of Q2 2016 after selling out during the quarter.
  • Boothbay Fund Management sold 19,184 Impax Laboratories, Inc. shares in Q2 2016, an estimated $614K.
  • Boothbay Fund Management first reported a position in Impax Laboratories, Inc. in Q1 2016 and held it in 1 quarter.
  • Boothbay Fund Management's Impax Laboratories, Inc. position peaked at $614K in Q1 2016.
  • 198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2016.

Based on Boothbay Fund Management's 13F filing for Q2 2016, filed 15 Aug 2016.